[1]黄觅,彭高高,刘常鲲,等.同源点针刺疗法治疗肌少-骨质疏松症的临床疗效观察[J].中国中医骨伤科杂志,2025,33(10):19-23+28.[doi:10.20085/j.cnki.issn1005-0205.251004]
　HUANG Mi,PENG Gaogao,LIU Changkun,et al.Clinical Efficacy Observation of Tongyuandian Acupuncture Therapy in the Treatment of Sarcopenia-Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2025,33(10):19-23+28.[doi:10.20085/j.cnki.issn1005-0205.251004]
点击复制

同源点针刺疗法治疗肌少-骨质疏松症的临床疗效观察()

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第33卷
期数:
2025年10期
页码:
19-23+28
栏目:
临床研究
出版日期:
2025-10-15

文章信息/Info

Title:
Clinical Efficacy Observation of Tongyuandian Acupuncture Therapy in the Treatment of Sarcopenia-Osteoporosis
文章编号:
1005-0205(2025)10-0019-05
作者:
黄觅1; 彭高高2; 刘常鲲2; 吴汉卿2; 胡昭端2; 彭锐1; 2△
1武汉市中西医结合医院(武汉,430030)
2湖北中医药大学
Author(s):
HUANG Mi1; PENG Gaogao2; LIU Changkun2; WU Hanqing2HU Zhaoduan2; PENG Rui1; 2△
1Wuhan Hospital of Traditional Chinese and Western Medicine,Wuhan 430030,China; 2Hubei University of Chinese Medicine,Wuhan 430065,China.
关键词:
肌少-骨质疏松症;  针刺;  同源点疗法;  养元通络;  临床观察
Keywords:
sarcopenia-osteoporosis;  acupuncture;  Tongyuandian acupuncture therapy;  Yangyuan Tongluo;  clinical observation
分类号:
R246.2
DOI:
10.20085/j.cnki.issn1005-0205.251004
文献标志码:
A
摘要:
目的:观察同源点针刺疗法治疗肌少-骨质疏松症患者的临床疗效。方法:选取2023年8月至2024年8月就诊的肌少-骨质疏松症患者,随机将患者分为对照组和观察组,每组各40例。对照组采用口服钙尔奇D(碳酸钙D3片)治疗,观察组在对照组治疗方案的基础上增加同源点针刺干预措施,2次/周,4周为1个疗程,共3个疗程,随访时间为6个月,排除本研究过程中退组和脱落的患者,最终观察组纳入33例,对照组纳入30例。比较观察组和对照组治疗前后骨密度(BMD)、SF-12生活质量评分、中医证候量化分级评分、简易体能状况量表(SPPB)评分、小腿周长及握力变化。结果:两组患者治疗前骨密度、SF-12生活质量评分、中医证候量化分级评分、SPPB评分、小腿周长及握力差异均无统计学意义(P>0.05)。治疗3个疗程后,观察组患者腰椎骨密度、SF-12生活质量评分中的生理健康评分(PCS)、SPPB评分及握力明显高于对照组,差异有统计学意义(P<0.05); 治疗后两组患者中医证候量化分级评分均降低,观察组中医证候量化分级评分低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者小腿周长差异无统计学意义(P>0.05)。结论:肌少-骨质疏松症患者接受同源点针刺治疗效果良好,同源点针刺疗法可提高肌少-骨质疏松症患者生存指数,维持骨密度并改善患者肌肉力量及躯体运动功能。
Abstract:
Objective:To observe the clinical efficacy of Tongyuandian acupuncture therapy in the treatment of patients with sarcopenia-osteoporosis.Methods:Sarcopenia-osteoporosis patients who attended from August 2023 to August 2024 were selected and randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with oral calcium(calcium carbonate D3),and the observation group was treated with Tongyuandian therapy on the basis of the control group,twice a week,4 weeks as a course of treatment,a total of 3 courses of treatment,with a follow-up time of 6 months,excluding the patients who withdrew from the group and fell off in the course of the study.Finally 33 cases were included in the observation group,and 30 cases were included in the control group.We compared the changes in bone mineral density(BMD),SF-12 quality of life scale,quantitative grading score of Chinese medicine evidence,score of short physical performance battery(SPPB),calf circumference,and grip strength before and after treatment in the observation group and the control group.Results:There were no statistically significant differences in BMD,SF-12 quality of life scale,quantitative grading score of Chinese medicine evidence,SPPB score,calf circumference,and grip strength between the two groups before treatment(P>0.05).After 3 courses of treatment,lumbar spine BMD,physiological health score(PCS)of SF-12 quality of life scale,SPPB score and grip strength of the observation group were significantly higher than those of the control group,and the difference was statistically significant(P<0.05).Quantitative grading score of Chinese medicine evidence were reduced in the two groups after the treatment,and the observation group's scores were lower than those of the control group,and the difference was statistically significant(P<0.05).The difference in calf circumference between the two groups after treatment was not statistically significant(P>0.05).Conclusion:Patients with sarcopenia-osteoporosis are well treated with Tongyuandian acupuncture therapy,which improves survival index,maintains bone density and improves muscle strength and somatic motor function in sarcopenia-osteoporosis patients.

参考文献/References:

[1] 《中国老年骨质疏松症诊疗指南(2023)》工作组,中国老年学和老年医学学会骨质疏松分会,中国医疗保健国际交流促进会骨质疏松病学分会,等.中国老年骨质疏松症诊疗指南(2023)[J].中华骨与关节外科杂志,2023,16(10):865-885.
[2] 中华医学会老年医学分会.老年人肌少症防控干预中国专家共识(2023)[J].中华老年医学杂志,2023,42(2):144-153.
[3] 中国健康促进基金会肌少-骨质疏松症专家共识委员会.肌少-骨质疏松症专家共识[J].中国骨质疏松杂志,2022,28(11):1561-1570.
[4] 黄觅,曾宇,杜世阳,等.同源点针刺法治疗膝痹病(骨关节炎)的临床疗效评价研究[J].时珍国医国药,2022,33(3):656-658.
[5] FAILDE I,MEDINA P,RAMÍREZ C,et al.Assessing health-related quality of life among coronary patients:SF-36 vs SF-12[J].Public Health,2009,123(9):615-617.
[6] 中华中医药学会.绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版)[J].中医正骨,2020,32(2):1-13.
[7] LIU D Q,WANG S J,LIU S,et al.Frontiers in sarcopenia:advancements in diagnostics,molecular mechanisms,and therapeutic strategies[J].Molecular Aspects of Medicine,2024,97:101270.
[8] COLAIANNI G,STORLINO G,SANESI L,et al.Myokines and osteokines in the pathogenesis of muscle and bone diseases[J].Current Osteoporosis Reports,2020,18(4):401-407.
[9] PIVONKA P,PARK A,FORWOOD M R.Functional adaptation of bone:the mechanostat and beyond[M]//PIVONKA P.Multiscale mechanobiology of bone remodeling and adaptation.Cham:Springer International Publishing,2018:1-60.
[10] SEVERINSEN M C K,PEDERSEN B K.Muscle-organ crosstalk:the emerging roles of myokines[J].Endocrine Reviews,2020,41(4):594-609.
[11] KIRK B,FEEHAN J,LOMBARDI G,et al.Muscle,bone,and fat crosstalk:the biological role of myokines,osteokines,and adipokines[J].Current Osteoporosis Reports,2020,18(4):388-400.
[12] WANG T Y,ZHENG Y S,JIANG S D,et al.Irisin in degenerative musculoskeletal diseases:functions in system and potential in therapy[J].Pharmacological Research,2024,210:107480.
[13] LU W H,XIAO W F,XIE W Q,et al.The role of osteokines in sarcopenia:therapeutic directions and application prospects[J].Frontiers in Cell and Developmental Biology,2021,9:735374.
[14] LARA-CASTILLO N,JOHNSON M L.Bone-muscle mutual interactions[J].Current Osteoporosis Reports,2020,18(4):408-421.
[15] JAUFFRET C,PÉRICHON R,LAMER A,et al.Association between sarcopenia and fracture risk in a population from the UK Biobank database[J].Journal of Bone and Mineral Research,2023,38(10):1422-1434.
[16] RIPPL M,GRUPP P,MARTINI S,et al.Characteristics of patients with very high fracture risk in a community-dwelling geriatric cohort[J].Bone,2025,192:117366.
[17] LIU C,LIU N Y,XIA Y,et al.Osteoporosis and sarcopenia-related traits:a bi-directional Mendelian randomization study[J].Frontiers in Endocrinology,2022,13:975647.
[18] BONNET N,BOURGOIN L,BIVER E,et al.RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass[J].The Journal of Clinical Investigation,2019,129(8):3213-3223.
[19] YANG F K,LIU Z J,CHEN W.Advances in research on pharmacotherapy of sarcopenia[J].Aging Medicine,2021,4(3):221-233.
[20] KIRK B,ZANKER J,DUQUE G.Osteosarcopenia:epidemiology,diagnosis,and treatment-facts and numbers[J].Journal of Cachexia,Sarcopenia and Muscle,2020,11(3):609-618.
[21] 邢彬,刘聪龙,张海莲,等.神经肌肉电刺激预防老年肌萎缩的机制研究[J].中华物理医学与康复杂志,2022,44(4):381-384.
[22] 邢正,郭兰兰,李世田,等.神经肌肉电刺激对肌少-骨质疏松大鼠骨血管及循环外泌体miRNA表达的影响[J].中国运动医学杂志,2023,42(12):959-970.
[23] 刘晏东,邓强,彭冉东,等.基于“肝-脾-肾”轴探讨中医药防治肌少-骨质疏松[J].中国老年学杂志,2024,44(23):5878-5883.
[24] 张通海,王礼宁,马勇,等.基于五体理论探讨五体与肌少-骨质疏松症的关系及肌少-骨质疏松症的治疗[J].中医正骨,2024,36(7):51-54.
[25] 谭国志,林贤灿,黄佳纯,等.基于异病同治理论探讨肌少症与骨质疏松症的治疗原则[J].世界中西医结合杂志,2024,19(6):1260-1264.
[26] 彭锐.同源点疗法:一“点”即通的经络诊疗方案[M].北京:中国中医药出版社,2022:8-16.
[27] 王浩越,李国华.肌少症与骨质疏松症的相关性的研究进展[J].联勤军事医学,2023,37(11):984-988.
(收稿日期:2025-05-15)

备注/Memo

备注/Memo:
基金项目:湖北省自然科学基金项目(2023AFD141)
△通信作者 E-mail:974831374@qq.com
更新日期/Last Update: 2025-10-10